Complete clinical responses to cancer therapy caused by multiple divergent approaches: A repeating theme lost in translation

Cancer Management and Research

Volumn 4, Issue 1, 2012, Pages 137-149

  Coventry, Brendon J ^a   Ashdown, Martin L ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Chemotherapy; Common pathways; Complete responses; Immune modulation; Immune response; Immunotherapy; Oscillation; Regulatory T cells; Translational research

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; BEVACIZUMAB; CANCER VACCINE; CYTOKINE; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; DIETHYLSTILBESTROL; ESTROGEN; ESTROGEN RECEPTOR; EVEROLIMUS; HORMONE INHIBITOR; IMMUNOLOGIC AGENT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; PAZOPANIB; PROGESTERONE RECEPTOR; SORAFENIB; SUNITINIB; TAMOXIFEN; TICILIMUMAB; TRASTUZUMAB; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; ALOPECIA; APOPTOSIS; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CARDIOVASCULAR SYMPTOM; DIARRHEA; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; GASTRITIS; GLIOBLASTOMA; HORMONE INHIBITION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; INFECTION; INOPERABLE CANCER; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MELANOMA; METABOLIC INHIBITION; MUCOSA INFLAMMATION; NEOPLASM; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHUMAN; PATIENT COMPLIANCE; PERFORATION; PROSTATE CANCER; REVIEW; SOLID TUMOR; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 84864041109     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S31887     Document Type: Review

References (59)

1. Kiberstis PA, Travis J. Celebrating a glass half-full. Science. 2006;312: 1157.
2. Murphy KM, Topel, RH. The value of health and longevity. J Polit Econ. 2006;114:871-904.
3. US National Institues of Health. President's Cancer Panel. 2007-2008 annual report. Available from: http://deainfo.nci.nih.gov/advisory/pcp/ pcp.htm. Accessed April 23, 2012.
4. Morgan G, Ward R, Barton M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol). 2004;16:549-560.
5. DeVita VT Jr, Lawrence TS, Rosenberg SA, DePinho RA, Weinberg RA, editors. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 9th ed. New York: Lippincott; 2011.
6. Coventry BJ, Ashdown ML, Quinn MA, Markovic SN, Yatomi-Clarke SL, Robinson AP. CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? J Transl Med. 2009;7:102.
7. Ashdown ML, Coventry BJ. A Matter of Time. Australasian Science. May 2010:18-20.
8. Coventry BJ, et al. Immuno-chemotherapy using repeated vaccine treatment can produce successful clinical responses in advanced metastatic melanoma. J Cancer Ther. 2010;1:205-213.
9. Leontovich AA, Dronca RS, Suman VJ, et al. Fluctuation of systemic immunity in melanoma and implications for timing of therapy. Front Biosci (Elite Ed). 2012;4:958-975.
10. Leslie M. 'Danger signals' from dying cells jolt immune system into action. Science. Epub February 9, 2012.
11. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174(12):7516-7523.
12. Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys. Epub December 28, 2011.
13. Tabachnyk M, Distel LV, Büttner M, et al. Radiochemotherapy induces a favourable tumour infiltrating inflammatory cell profile in head and neck cancer. Oral Oncol. Epub February 20, 2012.
14. Olivier KR, Schild SE, Morris CG, Brown PD, Markovic SN. A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer. 2007;110:1791-1795.
15. Morton R, editor. Treatment of Metastatic Melanoma. Croatia: Intech Publishers; 2011.
16. Petersen RP, Hanish SI, Haney JC, et al. J Thorac Cardiovasc Surg. 2007;133(1):104-110.
17. Essner R, Lee JH, Wanek LA, Itakura H, Morton DL. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg. 2004;139(9):961-966; discussion 966-967.
18. Balch C, Houghton A, Sober A, Soong S. Cutaneous Melanoma, 4th ed. St Louis: Quality Medical Publishing, Inc; 2003.
19. Ollila DW, Hsueh EC, Stern SL, Morton DL. Metastasectomy for recurrent stage IV melanoma. J Surg Oncol. 1999;71(4):209-213.
20. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181(3): 193-201.
21. Wong JH, Euhus DM, Morton DL. Surgical resection for metastatic melanoma to the lung. Arch Surg. 1988;123(9):1091-1095.
22. Loi S, de Azambuja E, Pugliano L, Sotiriou C, Piccart MJ. HER2-overexpressing breast cancer: time for the cure with less chemotherapy? Curr Opin Oncol. 2011;23(6):547-558.
23. Murphy CG, Fornier M. HER2-positive breast cancer: beyond trastuzumab. Oncology (Williston Park). 2010;24(5):410-415.
24. Abramson V, Arteaga CL. New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Clin Cancer Res. 2011;17(5):952-958.
25. Grant SL, Hammacher A, Douglas AM, et al. An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells. Oncogene (England). 2002;21(3):460-474.
26. Halaban R, Zhang W, Bacchiocchi A, et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cells. Pigment Cell Melanoma Res. 2011;23(2):190-200.
27. Ernstoff MS. Been there, not done that-melanoma in the age of molecular therapy. N Engl J Med. 2011;364(26):2547-2548.
28. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-819.
29. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
30. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol. 2011;8(7):426-433.
31. Sosman JA, Kim KB, Schuchter L. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-714.
32. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464(7287):431-435.
33. Grivas PD, Redman BG. Immunotherapy of kidney cancer. Curr Clin Pharmacol. 2011;6(3):151-163.
34. Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med. 2005;202(10):1375-1386.
35. McNally A, Hill GR, Sparwasser T, Thomas R, Steptoe RJ. CD4CD25regulatory T cells control CD8T-cell effector differentiation by modulating IL-2 homeostasis. Proc Natl Acad Sci U S A. 2011;108(18):7529-7534.
36. Sojka DK, Hughson A, Sukiennicki TL, Fowell DJ. Early kinetic window of target T cell susceptibility to CD25regulatory T cell activity. J Immunol. 2005;175(11):7274-7280.
37. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4CD25(hi) Foxp3regulatory T cells in cancer patients. Blood. 2006;107(6):2409-2414.
38. Coventry BJ, Ashdown ML, Markovic SN. Immune therapies for cancer: bimodality-the blind spot to clinical efficacy-lost in translation. J Immunother. 2011;34(9):717.
39. Biton J, Boissier MC, Bessis N. TNF: activator or inhibitor of regulatory T cells? Joint Bone Spine. 2012;79(2):119-123.
40. Filippi CM, Juedes AE, Oldham JE, et al. Transforming growth factorbeta suppresses the activation of CD8T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunity. Diabetes. 2008;57(10):2684-2692.
41. O'Connor W Jr, Kamanaka M, Booth CJ, et al. A protective function for interleukin 17 in T cell-mediated intestinal inflammation. Nat Immunol. 2009;10(6):603-609.
42. Chen X, Oppenheim JJ. TNF-alpha: an activator of CD4FoxP3 TNFR2regulatory T cells. Curr Dir Autoimmun. 2010;11:119-134.
43. Evangelidou M, Tseveleki V, Vamvakas SS, Probert L. TNFRI is a positive T-cell costimulatory molecule important for the timing of cytokine responses. Immunol Cell Biol. 2010;88(5):586-595.
44. Chen X, Oppenheim JJ. Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Lett. 2011;585(23):3611-3618.
45. Comerford I, Bunting M, Fenix K, et al. An immune paradox: how can the same chemokine axis regulate both immune tolerance and activation?: CCR6/CCL20: a chemokine axis balancing immunological tolerance and inflammation in autoimmune disease. Bioessays. 2010;32(12):1067-1076.
46. Mumm JB, Emmerich J, Zhang X, et al. IL-10 elicits IFN-dependent tumor immune surveillance. Cancer Cell. 2011;20(6):781-796.
47. A delicate balance: tweaking IL-2 immunotherapy. Nat Med. 2012;18(2):208-209.
48. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18(7):2039-2047.
49. Jain N, Nguyen H, Chambers C, Kang J. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci U S A. 2011;107(4):1524.
50. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
51. Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;29:332(6029):600-603.
52. Coventry B, Heinzel S. CD1a in human cancers: a new role for an old molecule. Trends Immunol. 2004;25(5):242-248.
53. Xu H, Cao X. Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine. Front Med. 2011;5(4):323-332.
54. Pandolfi F, Cianci R, Pagliari D, et al. The immune response to tumors as a tool toward immunotherapy. Clin Dev Immunol. 2011;2011:894704.
55. Tuyaerts S. Dendritic cell therapy for oncology roundtable conference. J Immune Based Ther Vaccines. 2011;9(1):1.
56. Nakai N, Hartmann G, Kishimoto S, Katoh N. Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters. Pigment Cell Melanoma Res. 2010;23(5):607-619.
57. Tuma RS. Large trials, small gains: is change on the way? J Natl Cancer Inst. 2010;102(16):1216-1217, 1223.
58. Glunde K, Bhujwalla ZM. Metabolic tumor imaging using magnetic resonance spectroscopy. Semin Oncol. 2011;38(1):26-41.
59. Glunde K, Jiang L, Moestue SA, Gribbestad IS. MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer. NMR Biomed. 2011;24(6):673-690.